BofA warns Fed risks policy mistake with early rate cuts
Select Medical (TASE:BLWV) Holdings Corporation (NYSE:SEM), a $2.4 billion healthcare company that has demonstrated strong momentum with a 14% gain in the past week, has approved changes to its Non-Employee Director Compensation Policy and amended its corporate bylaws and charter, as disclosed in a recent 8-K filing with the U.S. Securities and Exchange Commission (SEC). According to InvestingPro analysis, the company maintains a "GOOD" financial health score, suggesting solid operational fundamentals.
During the annual meeting on April 24, 2025, shareholders voted to approve the revised compensation policy for non-employee directors. This policy outlines the cash and equity compensation for these directors, which includes a quarterly cash retainer of $18,000, with the option to receive fully-vested shares of the company’s common stock instead. Additionally, directors will receive a $3,000 attendance fee for each in-person board meeting and $600 for telephonic meetings, along with fees for participating on board committees. These governance changes come as InvestingPro data shows the company is expected to grow its net income this year, with analysts forecasting earnings of $1.09 per share for fiscal year 2025.
Furthermore, an amendment to the company’s Amended and Restated Certificate of Incorporation was approved, effectively eliminating supermajority voting requirements. This amendment lowers the vote requirement to a simple majority of outstanding shares to amend the company’s bylaws and certain provisions of the charter. Following this amendment, the board also approved a change to the bylaws, which was effective immediately upon the amendment of the charter. Both the Certificate of Amendment to the Charter and Amendment No. 1 to Bylaws were filed with the Delaware Secretary of State on April 28, 2025.
In addition to these changes, shareholders at the annual meeting voted on several other proposals, including the election of four Class I directors, a non-binding advisory vote on executive compensation, and the ratification of PricewaterhouseCoopers LLP as the company’s independent auditor for the fiscal year ending December 31, 2025. With the company’s next earnings report due on May 1, 2025, investors can access comprehensive analysis and additional insights through InvestingPro, which offers exclusive access to detailed financial metrics, Fair Value assessments, and expert research reports covering over 1,400 US stocks.
The information provided in this article is based on the press release statement from Select Medical Holdings Corporation.
In other recent news, Semperit reported a significant turnaround in its financial performance for Q4 2024, achieving a profit of €11.5 million compared to a €17 million loss in 2023. Despite this positive earnings result, the company’s revenue remained flat at €1.31 billion, missing the forecast of €1.55 billion. This revenue shortfall contributed to investor concerns, leading to an 8.16% drop in the company’s stock in after-hours trading. Additionally, Semperit’s earnings per share of €0.18 exceeded analyst expectations of €0.16. Looking forward, Semperit has projected an operational EBITDA of €70-90 million for 2025, with plans for long-term EBITDA growth to €120 million by 2026. Meanwhile, Mizuho (NYSE:MFG) initiated coverage on Select Medical Holdings Corporation with an Outperform rating and set a price target of $25.00 per share. The firm’s outlook is based on Select Medical’s strong position in post-acute care services and its growth prospects in the inpatient rehabilitation market. Mizuho also noted potential margin expansion in outpatient rehabilitation services and possible value creation through share repurchases or mergers and acquisitions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.